Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
How should a missed or incomplete loading dose of Emgality® ▼ (galcanezumab) be managed?
In the event of a missed or incomplete loading dose of galcanezumab, complete the loading dose as soon as possible. Then continue with the monthly maintenance dose from the date of last dose.
Management of Missed or Incomplete Galcanezumab Loading Dose
The recommended dose is 120 mg galcanezumab injected subcutaneously once monthly, with a 240 mg loading dose as the initial dose.1
Patients should be instructed to inject a missed dose as soon as possible and then resume monthly dosing.1
Pharmacokinetic Considerations
In healthy subjects and patients with episodic or chronic migraine, galcanezumab has a
Pharmacokinetic modeling of phase 3 data confirmed that
the 240 mg loading dose achieved steady-state galcanezumab concentrations by month 1 for the 120 mg monthly dose regimen, and
without a loading dose, the 120 mg monthly dose did not achieve steady state until 4 to 5 months.3
1. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
3. Kielbasa W,Quinlan T. Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol. 2020;60(2):229-239. http://dx.doi.org/10.1002/jcph.1511
Glossary
t1/2 = elimination half-life
Tmax = time of maximum observed drug concentration
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: June 05, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays